Clinical Trial Detail

NCT ID NCT04308330
Title Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies (NYMC195)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors New York Medical College
Indications

Advanced Solid Tumor

central nervous system cancer

Therapies

Cefixime + Irinotecan + Temozolomide + Vincristine Sulfate

Cefixime + Irinotecan + Temozolomide + Vincristine Sulfate + Vorinostat

Age Groups: adult child

No variant requirements are available.